Bronchogen

This study addressed two distinct questions that must remain separated. In HeLa-cell localization experiments, fluorescence-labeled short peptides including Pinealon (Glu-Asp-Arg) were observed in the cytoplasm, nucleus, and nucleolus; because the peptides were fluorescently labeled, these observations do not establish identical cellular or nuclear entry for unmodified Pinealon, blood-brain-barrier penetration, or in-vivo pharmacologic intracellular exposure. Separately, the initial/intact peptides were examined in vitro for interaction with deoxyribooligonucleotides and DNA-ethidium-bromide complexes. The interaction behavior was peptide- and sequence-dependent and was influenced by cytosine methylation; Pinealon/EDR showed biochemical preference within CNG/CAG-containing oligonucleotide sequences. These findings support in-vitro nucleic-acid interaction only and do not establish promoter occupancy, universal CAG-site binding, specific human-gene targeting, or transcriptional regulation in cells or in vivo.

Reports anti-inflammatory and regenerative pulmonary markers associated with Bronchogen in an animal model.

Animal study reporting Bronchogen effects on pulmonary remodeling measures.

Reports DNA thermal-stability effects of Bronchogen. NOTE: this paper's own title states the sequence as Ala-Asp-Glu-Leu, an outlier versus later papers in the same lineage which converge on Ala-Glu-Asp-Leu (AEDL) -- retained here as a documented source inconsistency, not the canonical sequence.

A cross-species short-peptide gene-expression screen in tobacco (Nicotiana tabacum) plants that includes the AEDL/Bronchogen sequence. Useful only for sequence-naming corroboration -- this is a PLANT gene-expression study, not human or mammalian biology, and must not be cited as biological/mechanistic support for a human respiratory claim.

Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass.